rBIO announced that it has completed all the required analytical characterizations of its insulin biosimilar, R-biolin. This positions the company to file for the 351(k) drug submission process — an abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference product.
Read MoreWith its patented technology that can extend metalens field of view (FOV) to almost 180 degrees without sacrificing imaging quality, 2Pi Optics outperforms conventional wide-FOV refractive optics in size, weight, performance, and cost.
Read MoreIt’s incredibly important to have a strong brand image and supporting story before you begin PR. Here are some of our recent branding and website success stories with some hugely promising science startups.
Read More